Education
About Us
Working with TipRanks
Follow Us
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Total Valuation
Kazia Therapeutics has a market cap or net worth of $65.64M. The enterprise value is $11.06M.
Market Cap$65.64M
Enterprise Value$11.06M
Share Statistics
Kazia Therapeutics has 11,335,992 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,335,992
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kazia Therapeutics’s return on equity (ROE) is 2.49 and return on invested capital (ROIC) is 172.61%.
Return on Equity (ROE)2.49
Return on Assets (ROA)-3.42
Return on Invested Capital (ROIC)172.61%
Return on Capital Employed (ROCE)1.78
Revenue Per Employee4.67K
Profits Per Employee-2.30M
Employee Count9
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kazia Therapeutics is ―. Kazia Therapeutics’s PEG ratio is 0.00768.
PE Ratio―
PS Ratio248.45
PB Ratio-1.26
Price to Fair Value-1.26
Price to FCF-0.79
Price to Operating Cash Flow-1.72
PEG Ratio0.00768
Income Statement
In the last 12 months, Kazia Therapeutics had revenue of 42.00K and earned -20.70M in profits. Earnings per share was -18.90.
Revenue42.00K
Gross Profit42.00K
Operating Income-14.22M
Pretax Income-22.45M
Net Income-20.70M
EBITDA-13.28M
Earnings Per Share (EPS)-18.90
Cash Flow
In the last 12 months, operating cash flow was -8.35M and capital expenditures 4.14M, giving a free cash flow of -4.21M billion.
Operating Cash Flow-8.35M
Free Cash Flow-4.21M
Free Cash Flow per Share-0.37
Dividends & Yields
Kazia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change59.90%
50-Day Moving Average7.17
200-Day Moving Average7.48
Relative Strength Index (RSI)45.94
Average Volume (3m)209.48K
Important Dates
Kazia Therapeutics upcoming earnings date is Aug 28, 2025, TBA (Confirmed).
Last Earnings DateFeb 19, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend Date―
Financial Position
Kazia Therapeutics as a current ratio of 0.35, with Debt / Equity ratio of -4.77%
Current Ratio0.35
Quick Ratio0.35
Debt to Market Cap0.04
Net Debt to EBITDA0.30
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kazia Therapeutics has paid -1.75M in taxes.
Income Tax-1.75M
Effective Tax Rate0.08
Enterprise Valuation
Kazia Therapeutics EV to EBITDA ratio is -0.49, with an EV/FCF ratio of -0.49.
EV to Sales154.43
EV to EBITDA-0.49
EV to Free Cash Flow-0.49
EV to Operating Cash Flow-0.49
Balance Sheet
Kazia Therapeutics has $4.34M in cash and marketable securities with $396.00K in debt, giving a net cash position of $3.95M billion.
Cash & Marketable Securities$4.34M
Total Debt$396.00K
Net Cash$3.95M
Net Cash Per Share$0.35
Tangible Book Value Per Share-$8.57
Margins
Gross margin is 100.00%, with operating margin of -33850.00%, and net profit margin of -49290.48%.
Gross Margin100.00%
Operating Margin-33850.00%
Pretax Margin-53447.62%
Net Profit Margin-49290.48%
EBITDA Margin-31626.19%
EBIT Margin-33850.00%
Analyst Forecast
The average price target for Kazia Therapeutics is $19.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$19.00
Price Target Upside195.03% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-98.25%
EPS Growth Forecast63.05%